{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002559","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.836353+00:00","generated_at":"2026-05-17T22:31:07.588777+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation","bullets":["SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).","Dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutation at nanomolar concentrations.","Nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutation, extending efficacy beyond pancreatic cancer.","Data covers three major KRAS-driven cancers: pancreatic, colorectal, and lung; on track for Phase 2/3 trial in Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002559","json":"https://secwatch.observer/filing/0001178913-25-002559.json","markdown":"https://secwatch.observer/filing/0001178913-25-002559.md","text":"https://secwatch.observer/filing/0001178913-25-002559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/0001178913-25-002559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/zk2533519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:31:07.588777+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}